HIV-Related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab

We present a case of a patient with well-controlled human immunodeficiency virus (HIV) infection and refractory classical Hodgkin lymphoma (HL) treated with nivolumab as fifth-line treatment, who achieved complete response (CR) by positron emission tomography –computed tomography (PET/CT). To our knowledge, this is the second case report of a patient exhibiting nivolumab’s response, and first reported CR in the setting of HIV-associated HL (HIV-HL).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research

Related Links:

Publication date: Available online 4 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rustain Morgan, Mark Perry, Jennifer Kwak, Alexandria Jensen, Manali KamdarAbstractIntroductionMantle cell lymphoma (MCL) is a rare subtype of non–Hodgkin lymphoma and requires both bone marrow biopsy and fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to correctly stage the disease at diagnosis. However, accurate identification of bone marrow involvement by lymphoma on FDG PET/CT scans has not been previously demonstrated. We hypothesized that a voxel-based analysis of...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur study has shown that 90% of PTCL cases will be FDG avid. However, PET/CT was not predictive for PFS or OS at any point. The only predictive factor was the presence of lymphopenia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Mantle cell lymphoma is a rare disease that requires bone marrow sampling for correct staging. However, the results of the present retrospective, multi-institutional, 20-patient study suggest that a fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography voxel-based threshold, with a sensitivity of 100% and specificity of 87.5%, might eliminate the need for bone marrow biopsy for some patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We examined the role of positron emission tomography/computed tomography (PET/CT) in a retrospective study of 40 patients. Of the 40 patients, 90% had fluorine-18 fluorodeoxyglucose-avid findings on PET/CT at diagnosis. The interim PET/CT and end of treatment PET/CT results were not prognostic for progression-free survival (PFS) or overall survival (OS). On multivariate analysis, only lymphopenia remained prognostic for PFS and OS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Non –Burkitt B-cell lymphoma with a rearrangement of MYC is an aggressive lymphoma that can fail initial treatment. We reviewed the data from 28 patients and investigated whether the mid-treatment positron emission tomography/computed tomography (PET/CT) scan could predict treatment failure. The results of that PET/CT scan did not predict in which patients the initial treatment would fail. Therefore, it should not be used to guide treatment decisions in this population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: CT Scan | Hematology | Leukemia | Lymphoma | Myeloma | PET Scan